Viatris. has filed a patent for the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine and its salt forms. The patent also includes novel polymorphic forms of these salts. The patent claim specifically mentions the product (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate, which is formed through a method involving tert-butyl(R)-3-vinylpyrrolidine-1-carboxylate as an intermediate. GlobalData’s report on Viatris gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Viatris Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Viatris, Cancer treatment biomarkers was a key innovation area identified from patents. Viatris's grant share as of September 2023 was 57%. Grant share is based on the ratio of number of grants to total number of patents.

(r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate synthesis

Source: United States Patent and Trademark Office (USPTO). Credit: Viatris Inc

A recently filed patent (Publication Number: US20230295126A1) claims a product called (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate. This product is formed using a specific method that involves the use of tert-butyl(R)-3-vinylpyrrolidine-1-carboxylate as an intermediate compound.

The patent also mentions that the tert-butyl(R)-3-vinylpyrrolidine-1-carboxylate can be formed through the intermediacy of several other compounds. These compounds include diethyl (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonate, (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonic acid, tert-butyl(R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate, and tert-butyl(R)-3-(2-iodoethyl)pyrrolidine-1-carboxylate.

This patent claim highlights a specific product and the method used to produce it. The product, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate, is formed through the use of tert-butyl(R)-3-vinylpyrrolidine-1-carboxylate as an intermediate compound. The patent also mentions alternative compounds that can be used to produce tert-butyl(R)-3-vinylpyrrolidine-1-carboxylate.

This patent claim provides valuable information for researchers and companies working in the field. The specific product and method described in the claim can potentially have applications in various industries, such as pharmaceuticals or chemical synthesis. Researchers and companies can use this information to further explore the potential uses and benefits of the claimed product and its production method.

It is important to note that this media summary is based solely on the information provided in the patent claim. Further research and analysis would be required to fully understand the significance and potential impact of this patent claim in the relevant field.

To know more about GlobalData’s detailed insights on Viatris, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies